This funding will help support research across epigenetics, immunology and cell signaling.
The Biotechnology and Biological Sciences Research Council (BBSRC) has awarded the Babraham Institute £48 million following a five-year review to support core research into the key mechanisms that maintain the health of cells, tissues and organs. I invested.
Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signaling.
The Institute of Life Sciences focuses on understanding the biology associated with maintaining health, especially in protecting and maximizing health late in life.
From 2024 to 2028, BBSRC’s new investments will improve the ability to protect health and counter age-related decline, including cellular responses to stress, epigenetic regulation across the life course, immunity, resilience and repair. It aims to support three strategic research programmes.
In close collaboration with partners across academia, including other research institutions strategically supported by BBSRC and companies based at the Babraham Research Campus, research will be carried out through the Babraham Institute’s team of international experts.
The funding comes from a wider investment worth £424m by BBSRC to support a new portfolio of strategically important research across eight UK bioscience institutions, announced in May 2023. .
This funding aims to significantly strengthen the UK’s ability to deliver world-leading research with social and economic impact.
Professor Guy Poppy, BBSRC’s Interim Executive Chair, commented: “BBSRC’s strategic investment will help us harness the power of bioscience for a healthier and more resilient future.” “The Babraham Institute is an important component of domestic and international research institutions.” Bioscience Research and Innovation Ecosystem”.
Dr Simon Cooke, director of the Babraham Institute, said: “From understanding the early stages of development to ensuring that vaccines provide strong protection for older people, each discovery makes a difference to human health and wellbeing. Probably.”
Earlier this year, in January, at the Babraham Institute’s flow cytometry facility. cooperated The partnership with PlaqueTec aims to develop and improve treatments for coronary artery disease, a type of heart disease that kills around 68,000 people a year in the UK.
